A directory of where to buy chemicals in the USA, including: distributors, industrial manufacturers, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the suppliers website for prices or more information.
| Product | Description | |
|---|---|---|
| PF-05020182 | PF05020182 is novel potent and selective Kv7.2/4 potassium channel opener originated by Pfizer. It can inhibit convulsions in the MES assay at doses tested, consistent with in vitro activity measure. PF-05020182 may be applicated for adjunctive treatment of refractory epilepsy. Uses: Refractory epilepsy. Synonyms: PF05020182; PF-05020182; PF 05020182; PF5020182; PF-5020182; PF 5020182. N-[4,6-Dimethoxy-2-(4-methoxy-1-piperidinyl)-5-pyrimidinyl]-3,3-dimethyl-butanamide. Grades: 98%. CAS No. 1354712-92-7. Molecular formula: C18H30N4O4. Mole weight: 366.46. |  |
| PF-05082566 | A fully humanized monoclonal antibody (mAb) that stimulates signaling through 4-1BB (CD-137), a protein expressed in many immune cells. Synonyms: Utomilumab; PF-2566; PF-5082566; PF 2566; PF 5082566; PF2566; PF5082566. CAS No. 1417318-27-4. | |
| PF-05085727 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. |  |
| PF 05089771 | PF 05089771 is a potent, orally active and selective arylsulfonamide Na v 1.7 inhibitor, with IC 50 values of 11 nM, 12 nM, 13 nM, 171 nM and 8 nM for hNa v 1.7, cynNa v 1.7, dogNa v 1.7, ratNa v 1.7, and musNa v 1.7, respectively. PF 05089771 is under the study for pain and diabetic neuropathy [1] [2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1235403-62-9. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-12883. |  |
| PF-05089771 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| PF-05089771 | PF-05089771, a Nav1.7 channel blocker, has been studied to have potential effect in the treatment of chronic neuropathic pain. It is still under Phase II clinical trial. IC50: 8.6 nM. Uses: Pf-05089771 is a nav1.7 channel blocker that has been studied to have potential effect in the treatment of chronic neuropathic pain. Synonyms: PF 05089771; PF05089771; PF-05089771; 4-(2-(3-amino-1H-pyrazol-4-yl)-4-chlorophenoxy)-5-chloro-2-fluoro-N-(thiazol-4-yl)benzenesulfonamide; SCHEMBL1095065; CHEMBL2325014; ZYSCOUXLBXGGIM-UHFFFAOYSA-N. Grades: 98%. CAS No. 1235403-62-9. Molecular formula: C18H12Cl2FN5O3S2. Mole weight: 500.35. | |
| PF 05089771 tosylate | PF 05089771 is a selective and potent inhibitor of the human voltage-gated sodium ion channel Nav1.7 with an IC50 value of 11 nM. It exhibits selectivity for Nav1.7 over other Nav1 channels (IC50 values are 0.11, 0.16, 0.85, 10, 11 and 25 μM for Nav1.2, Nav1.6, Nav1.1, Nav1.4, Nav1.3 and Nav1.5, respectively). Synonyms: 4-[2-(3-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-4-thiazolylbenzenesulfonamide tosylate; PF-05089771; PF05089771; PF 05089771 Tosylate. Grades: ≥98% by HPLC. CAS No. 1430806-04-4. Molecular formula: C18H12Cl2FN5O3S2.C7H8O3S. Mole weight: 672.56. | |
| PF 05105679 | PF-05105679 is a selective TRPM8 Antagonist with clinical efficacy in cold-related pain. IC50 value is 103 nM. It shows >100-fold selectivity for TRPM8 over a panel of receptors, ion channels and enzymes, including TRPV1 and TRPA1 ion channels. In Sep 2011, Pfizer completed a phase I trial for the treatment of neuropathic pain in Healthy volunteers in Belgium. Uses: Neuropathic pain;cold-related pain. Synonyms: PF-05105679; PF 05105679; PF05105679; PF-5105679; PF 5105679; PF5105679. 3-[[[(1R)-1-(4-Fluorophenyl)ethyl](3-quinolinylcarbonyl)amino]methyl]-benzoic acid, PF05105679, [(R)-3-[(1-(4-fluorophenyl)ethyl)(quinolin-3-ylcarbonyl)amino]methylbenzoic acid. Grades: 98%. CAS No. 1398583-31-7. Molecular formula: C26H21FN2O3. Mole weight: 428.45. | |
| PF-05105679 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| PF-05139962 | PF-05139962 is a novel potent mTOR inhibitor with excellent mTOR biochemical inhibition, cellular potency, kinase selectivity and in vitro ADME properties. PF-05139962 has pS473 and pS6 cellular IC50 = 48 and 6 nM respectively. PF-05139962 has great selectivity against other receptors and kinases. No genotoxicity was observed on this compound and no more than 25% inhibiton was observed for major CYP enzymes (3A4, 1A2, 2C9, 2D6) at 3 uM. This compound has LE = 0.35 and LipE up to 6.8 which is in a very desirable range for a kinase inhibitor. Synonyms: PF 05139962; PF05139962. CAS No. 1393712-18-9. Molecular formula: C21H27N5O4S. Mole weight: 445.54. | |
| PF 05175157 | PF-05175157 is a selective inhibitor of both acetyl-CoA carboxylase isoform ACC1 and isoform ACC2 dominant. IC50 values are 27 nM and 33 nM, respectively. It was originated by Pfizer. ACC inihibitors can inhibit de novo lipogenesis and increase β-oxidation of long-chain fatty acids. In Feb 2015, Phase-II for Type-2 diabetes mellitus in USA was discontinued. Uses: Type 2 diabetes mellitus. Synonyms: PF-05175157; PF05175157; 1,4-Dihydro-1'-[(2-methyl-1H-benzimidazol-6-yl)carbonyl]-1-(1-methylethyl)-spiro[5H-indazole-5,4'-piperidin]-7(6H)-one. Grades: 98%. CAS No. 1301214-47-0. Molecular formula: C23H27N5O2. Mole weight: 405.50. | |
| PF-05175157 | PF-05175157 is broad spectrum acetyl-CoA carboxylase (ACC) inhibitor with IC50s of 27.0, 33.0, 23.5 and 50.4 nM for ACC1 (human), ACC2 (human), ACC1 (rat), ACC2 (rat), respectively. Uses: Scientific research. Group: Signaling pathways. CAS No. 1301214-47-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-12942. | |
| PF-05175157 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| PF 05180999 | PF 05180999 is a potent and selective PDE2A inhibitor (IC50 = 1 nM), with 2000-fold selectivity for PDE2A over PDE10A. PF 05180999 was evaluated for schizophrenia and migraine, but no further development has been reported since 2014. Synonyms: 4-(1-Azetidinyl)-7-methyl-5-[1-methyl-5-[5-(trifluoromethyl)-2-pyridinyl]-1H-pyrazol-4-yl]-imidazo[5,1-f][1,2,4]triazine; PF05180999; PF-05180999; PF 5180999; PF5180999; PF-5180999; PF 5180999; PF999; PF-999; PF 999. Grades: ≥98% by HPLC. CAS No. 1394033-54-5. Molecular formula: C19H17F3N8. Mole weight: 414.39. | |
| PF-05180999 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| PF-05180999 | PF-05180999 (PF-999) is a phosphodiesterase 2A (PDE2A) inhibitor, with an IC 50 of 1.6 nM. Uses: Scientific research. Group: Signaling pathways. Alternative Names: PF-999. CAS No. 1394033-54-5. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-111371. | |
| PF-05212384 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| PF 05212384 (PKI-587) (N-[4-[[4-(Dimethylamino)-1-piperidi nyl]carbonyl]phenyl]-N'-[4-(4,6-di-4-morpholinyl-1, 3,5-triazin-2-yl)phenyl]urea) | Potent and selective dual inhibitor of PI 3-kinase/mTOR (IC50 values are 0.4, 1.6 and 5.4nm for PI 3-Kalpha, mTOR and PI 3-Kgamma respectively). Exhibits selectivity over 234 other protein kinases (IC50 >10um). Potently inhibits tumor cell growth in 37 different tumor cell lines (IC50 < 100nm). Also exhibits antitumor activity in MDA-361, HCT-116, H1975 and U87MG xenograft models. Group: Biochemicals. Grades: Highly Purified. CAS No. 1197160-78-3. Pack Sizes: 10mg. US Biological Life Sciences. |  Worldwide |
| PF-05221304 | PF-05221304 Inhibitor. Uses: Scientific use. Product Category: T9209. CAS No. 1370448-25-1. |  |
| PF-05231023 | PF-05231023 is a long-acting FGF21 mimic. PF-05231023 can reduce the weight of non-human primates and patients with type 2 diabetes and improve blood lipid status. It is a PEG-based PROTAC linker that can be used to synthesize PROTAC. Synonyms: Mal-Amido-PEG2-C2-Amido-Ph-C2-CO-AZD; 2, 5-Dihydro-2, 5-Dioxo-N- (2- (2- (3-Oxo-3- ( (4- (3-Oxo-3- (2-Oxo-1-Azetidinyl) Propyl) Phenyl) Amino) Propoxy) Ethoxy) Ethyl) -1H-Pyrrole-1-Propanamide; 2, 5-Dihydro-2, 5-Dioxo-N- [2- [2- [3-Oxo-3- [ [4- [3-Oxo-3- (2-Oxo-1-Azetidinyl) Propyl] Phenyl] Amino] Propoxy] Ethoxy] Ethyl] -1H-Pyrrole-1-Propanamide. Grades: ≥98% by HPLC. CAS No. 1037589-69-7. Molecular formula: C26H32N4O8. Mole weight: 528.6. | |
| PF-05236216 hydrochloride | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| PF-05241328 | PF-05241328, a purely acidic molecule, is a selective inhibitor of human Nav1. 7 voltage-dependent sodium channels (IC50 = 31nM) for the treatment of pain. But PF-05241328 is studied to have poor solubility and likely solubility limited absorption. Synonyms: PF-05241328; PF 05241328; PF05241328; PF-5241328; PF 5241328; PF5241328. 1-(5-Chloro-6-(2-methylpropoxy)-3-pyridinyl)-3-methyl-N-(methylsulfonyl)-1H-indazole-5-carboxamide; 1H-Indazole-5-carboxamide, 1-(5-chloro-6-(2-methylpropoxy)-3-pyridinyl)-3-methyl-N-(methylsulfonyl)-. CAS No. 1387633-03-5. Molecular formula: C19H21ClN4O4S. Mole weight: 436.9179. | |
| PF-05274857 Hydrochloride | PF-05274857 Hydrochloride. Group: Biochemicals. Alternative Names: 1-(4-(5'-Chloro-3,5-dimethyl-[2,4'-bipyridin]-2'-yl)piperazin-1-yl)-3-(methylsulfonyl)propan-1-one Monohydrochloride. Grades: Highly Purified. Pack Sizes: 2.5mg. Molecular Formula: C20H26Cl2N4O3S, Molecular Weight: 473.42. US Biological Life Sciences. | Worldwide |
| PF-05297909 | PF-05297909, is a BACE inhibitor developed by Pfizer. Phase 1. Synonyms: PF-05297909; PF-5297909. | |
| PF-05883083-00 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| PF-06250112 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| PF-06260933 | PF-06260933 is an orally active and highly selective inhibitor of MAP4K4 with IC50s of 3.7 and 160 nM for kinase and cell, respectively. Uses: Scientific research. Group: Signaling pathways. CAS No. 1811510-56-1. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-19562. | |
| PF 06260933 dihydrochloride | PF 06260933 is a highly selective, orally active and small-molecule inhibitor of MAP4K4 (Mitogen-activated protein kinase kinase kinase kinase 4) (IC50 = 140 nM). It also inhibits MINK and TNIK (IC50= 8 and 13 nM, respectively). PF-06260933 dihydrochloride has been shown to improves fasting hyperglycemia in mice. Synonyms: 5-(4-Chlorophenyl)-[3,3'-bipyridine]-6,6'-diamine dihydrochloride; PF-06260933 dihydrochloride; PF06260933 dihydrochloride; PF 06260933 dihydrochloride. Grades: ≥98% by HPLC. CAS No. 1883548-86-4. Molecular formula: C16H13ClN4.2HCl. Mole weight: 369.68. | |
| PF-06260933 dihydrochloride | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| PF-06263276 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| PF 06273340 | PF 06273340 is a potent and selective, orally bioavailable pan-Trk kinase inhibitor with IC50 of 6, 2, and 1 nM for Trk A, B and C, respectively. PF 06273340 is selective for Trk over a panel of ion channels, receptors and other enzymes. It shows efficacy in a rodent model of inflammatory pain. Synonyms: N-[5-[[2-Amino-7-(2-hydroxy-1,1-dimethylethyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]carbonyl]-3-pyridinyl]-5-chloro-2-pyridineacetamide; PF-06273340; PF 06273340; PF06273340; PF-6273340; PF 6273340; PF6273340. Grades: ≥98% by HPLC. CAS No. 1402438-74-7. Molecular formula: C23H22ClN7O3. Mole weight: 479.93. | |
| PF-06273340 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| PF-06281355 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| PF-06282999 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| PF-06282999 | PF-06282999 is a potent and selective myeloperoxidase inhibitor which is potential useful for the treatment of cardiovascular diseases. Uses: Scientific research. Group: Signaling pathways. CAS No. 1435467-37-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-19321. | |
| PF-06282999 | PF-06282999 is a selective myeloperoxidase Inhibitor originate by Pfizer. It showed good oral pharmacokinetics in preclinical species and robust irreversible inhibition of plasma MPO activity. In Mar 2015, Pfizer terminated phase I trial for the treatment of Acute coronary syndromes in Healthy volunteers in USA. Uses: Acute coronary syndromes. Synonyms: PF-06282999; PF06282999; PF06282999. 2-(6-(5-chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide. Grades: 98%. CAS No. 1435467-37-0. Molecular formula: C13H12ClN3O3S. Mole weight: 325.77. | |
| PF-06284674 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| PF-06297470 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| PF-06305591 dihydrate | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| PF-06372222 | PF-06372222 is a small molecule negative allosteric modulator (NAM) of glucagon receptor (GCGR), which helps treat type 2 diabetes. It is also an antagonist of the glucagon-like peptide-1 receptor GLP-1R, which can inhibit glucagon secretion and glucose-dependent insulin secretion. Synonyms: N-{4-[(R)-(3,3-Dimethylcyclobutyl)({6-[4-(Trifluoromethyl)-1h-Imidazol-1-Yl]Pyridin-3-Yl}Amino)Methyl]Benzene-1-Carbonyl}-Beta-Alanine. Grades: ≥98% by HPLC. CAS No. 1407592-99-7. Molecular formula: C26H28F3N5O3. Mole weight: 515.5. | |
| PF-06372865 | PF-06372865 is an orally active, α2/α3/α5 subtype-selective GABA A positive allosteric modulator (PAM). PF-06372865 is a high affinity ligand at GABA A receptors containing α1/α2/α3/α5 subunits ( K i s of 2.9 nM, 21 nM, 134 nM for α2, α1 PAM, α2 PAM, respectively), with low affinity for α4/α6 subunits. PF-06372865 can across the blood-brain barrier (BBB). PF-06372865 has anxiolytic activity and has the potential for epilepsy [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1614245-70-3. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-120874. | |
| PF 06409577 | PF 06409577 is a potent and selective allosteric activator of AMPK (EC50 values are 7 and >40000 nM for AMPKα1β1γ1 and AMPKα1β2γ1, respectively) for the potential treatment of diabetic nephropathy. PF-06409577 showed efficacy in a preclinical model of diabetic nephropathy. Synonyms: PF-06409577; PF06409577; PF-6409577; PF6409577; PF 6409577. Grades: ≥98% by HPLC. CAS No. 1467057-23-3. Molecular formula: C19H16ClNO3. Mole weight: 341.79. | |
| PF-06409577 | PF-06409577 is a potent and selective allosteric activator of AMPK ?1?1?1 isoform with an EC50 of 7 nM. Uses: Scientific research. Group: Signaling pathways. CAS No. 1467057-23-3. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-103683. | |
| PF-06409577 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| PF-06422913 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| PF 06424439 | PF 06424439 is a potent, selective and orally bioavailable Diacylglycerol Acyltransferase 2 ( DGAT2) inhibitor with DGAT2 IC50 ± SEM (nM) (human/rat/dog) 14 ± 1/38 ± 4/16 ± 1, which exhibits no significant activity at MGAT1-3 or DGAT1. It reduces triglyderide synthesis in human hepatocytes in vitro, and reduces plasma triglyceride and cholesterol levels in a rat dyslipidemia model. Synonyms: [(3R)-1-[2-[1-(4-Chloro-1H-pyrazol-1-yl)cyclopropyl]-3H-imidazo[4,5-b]pyridin-5-yl]-3-piperidinyl]-1-pyrrolidinylmethanone methanesulfonate; PF-06424439; PF06424439; PF 06424439; PF-6424439; PF-6424439; PF 6424439. Grades: ≥98% by HPLC. CAS No. 1469284-79-4. Molecular formula: C22H26ClN7O.CH4O3S. Mole weight: 536.05. | |
| PF-06424439 | PF-06424439 is an oral, potent and selective imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitor with an IC50 of 14 nM[1]. PF-06424439 is slowly reversible, time-dependent inhibitor, which inhibits DGAT2 in a noncompetitive mode with respect to the acyl-CoA substrate[2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1469284-78-3. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg. Product ID: HY-108341. | |
| PF-06424439 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| PF-06424439 Free base | PF-06424439, a imidazo-pyridin derivative, has been found to be a selective DGAT2 inhibitor that could be probably effective against dyslipidemic rodent in animal models. Synonyms: PF-06424439; PF06424439; PF 06424439; PF-6424439; PF-6424439; PF 6424439; (R)-(1-(2-(1-(4-chloro-1H-pyrazol-1-yl)cyclopropyl)-3H-imidazo[4,5-b]pyridin-5-yl)piperidin-3-yl)(pyrrolidin-1-yl)methanone. Grades: 98%. CAS No. 1469284-78-3. Molecular formula: C22H26ClN7O. Mole weight: 439.94. | |
| PF-06424439 methanesulfonate | PF-06424439 methanesulfonate is an oral, potent and selective imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitor with an IC50 of 14 nM[1]. PF-06424439 methanesulfonate is slowly reversible, time-dependent inhibitor, which inhibits DGAT2 in a noncompetitive mode with respect to the acyl-CoA substrate[2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1469284-79-4. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-108341A. | |
| PF-06439015 methanesulfonate salt | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| PF-06442609 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| PF-06442609 | PF-06442609 is a potent, metabolic stable γ-secretase modulators. It displayed a favorable rodent pharmacokinetic profile, and robust reductions of brain Aβ42 and Aβ40 were observed in a guinea pig time-course experiment. F-06442609 may be used for the treatment of Alzheimer's disease in the future. Uses: Alzheimer's disease. Synonyms: PF-06442609; PF 06442609; PF06442609; PF-6442609; PF 6442609; PF6442609. 2-((S)-1-(4-fluoro-2-((R)-1,1,1-trifluoropropan-2-yl)phenoxy)propan-2-yl)-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione. Grades: 98%. CAS No. 1402002-76-9. Molecular formula: C24H24F4N4O3. Mole weight: 492.47. | |
| PF-06446846 hydrochloride | PF-06446846 hydrochloride is an orally active and highly selective inhibitor of translation of Proprotein convertase subtilisin/kexin type 9 (PCSK9). PF-06446846 hydrochloride inhibits PCSK9 by inducing the ribosome to stall around codon 34[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1632250-50-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-120088A. | |
| PF-06446846 hydrochloride | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| PF-06447475 | PF06447475 is a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor. Leucine rich repeat kinase 2 (LRRK2) has been genetically linked to Parkinson's disease (PD) by genome-wide association studies (GWAS). The most common LRRK2 mutation, G2019S, which is relatively rare in the total population, gives rise to increased kinase activity. As such, LRRK2 kinase inhibitors are potentially useful in the treatment of PD. Synonyms: PF06447475; PF-06447475; PF 06447475; PF6447475; PF-6447475; PF 6447475. Grades: >98%. CAS No. 1527473-33-1. Molecular formula: C17H15N5O. Mole weight: 305.33. | |
| PF-06447475 | PF-06447475 is a highly potent, selective and brain penetrant LRRK2 inhibitor with an IC50 of 3 nM. Uses: Scientific research. Group: Signaling pathways. CAS No. 1527473-33-1. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 200 mg. Product ID: HY-12477. | |
| PF-06456384 trihydrochloride | PF-06456384 trihydrochloride is a highly potent and selective NaV1.7 inhibitor with an IC50 of 0.01 nM. PF-06456384 trihydrochloride has the potential for formalin pain model research[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1834610-75-1. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-118952A. | |
| PF-06456384 trihydrochloride | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| PF-06459988 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| PF-06459988 | PF-06459988 is a third-generation, irreversible epidermal growth factor receptor (EGFR) inhibitor. It can bind to and inhibit mutant forms of EGFR, including the secondary acquired resistance mutation T790M.PF-06459988 may have therapeutic benefits in tumors with T790M-mediated drug resistance. Preclinical trials in Non-small cell lung cancer in USA is on-going. Uses: Non-small cell lung cancer. Synonyms: PF-06459988; PF06459988; PF 06459988; PF-6459988; PF 6459988; PF6459988; 1-((3R,4R)-3-(((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)methyl)-4-methoxypyrrolidin-1-yl)prop-2-en-1-one. Grades: 98%. CAS No. 1428774-45-1. Molecular formula: C19H22ClN7O3. Mole weight: 431.88. | |
| PF-06462894 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| PF-06463922 acetate | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| PF 06465469 | PF 06465469 is a potent, covalent inhibitor of the nonreceptor tyrosine kinase Itk (IL-2 inducible T-cell kinase) (IC50 = 2 nM). It also shows inhibitory activity against Bruton's tyrosine kinase (BTK) (IC50 = 2 nM). Synonyms: (R)-3-(1-(1-Acryloylpiperidin-3-yl)-4-amino-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(3-methyl-4-(1-methylethyl))benzamide; PF-06465469; PF 06465469; PF06465469; PF-6465469; PF 6465469; PF6465469. Grades: ≥95% by HPLC. CAS No. 1407966-77-1. Molecular formula: C30H33N7O2. Mole weight: 523.63. | |
| PF-06465469 | PF-06465469 is a covalent inhibitor of ITK with an IC50 of 2?nM. PF-06465469 also inhibits BTK. PF-06465469 inhibits cell migration in response to CXCL12. PF-06465469 decreases PD-1 and LAG-3 expression. PF-06465469 can be used to study leukemia and T-cell lymphoma[1][2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1407966-77-1. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-108691. | |
| PF-06465469 | ?97% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| PF-06471553 | PF-06471553, isoindoline-5-sulfonamide, selectively inhibits MGAT3 with high in vitro potency and cell efficacy which displayed suitable PK properties in mouse and in vivo MGAT3 inhibition in a transgenic mouse model. Synonyms: PF-06471553; PF 06471553; PF06471553; PF-6471553; PF 6471553; PF6471553. N-(2-cyclobutyl-2H-1,2,3-triazol-4-yl)-2-(2-(3-methoxyphenyl)acetyl)isoindoline-5-sulfonamide. Grades: >98%. CAS No. 1808094-07-6. Molecular formula: C23H25N5O4S. Mole weight: 467.54. | |
| PF 06551600 malonate | PF 06551600 is a potent and selective JAK3 inhibitor with IC50 value of 33.1 μM, exhibiting >1,000-fold selectivity over JAK1 and JAK2. It inhibits phosphorylation of STAT5, induced by IL-2, IL-4, IL-7 and IL-15. It also inhibits Th1 and Th17 T-cell differentiation and function in vitro. Synonyms: 1-[(2S,5R)-2-Methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-propen-1-one malate. Grades: ≥98% by HPLC. CAS No. 2140301-97-7. Molecular formula: C15H19N5O·C3H4O4. Mole weight: 389.41. | |
| PF-06648671 | PF-06648671 is a novel, brain-penetrable, and orally active γ-secretase modulator (GSM). PF-06648671 reduces Aβ42 and Aβ40, with concomitant increases in Aβ37 and Aβ38 in vitro. PF-06648671 is used for the study of Alzheimers disease [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1587727-31-8. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-120789. | |
| PF-06649283 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
Our database is helping our users find suppliers everyday.
